Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
<p><strong>Background:</strong><br /> A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChA...
| Glavni autori: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Daljnji autori: | |
| Format: | Journal article |
| Jezik: | English |
| Izdano: |
Elsevier
2020
|
| _version_ | 1826260972209176576 |
|---|---|
| author | Voysey, M Clemens, SAC Madhi, SA Weckx, LY Folegatti, PM Aley, PK Angus, B Baillie, VL Barnabas, SL Bhorat, QE Bibi, S Briner, C Cicconi, P Collins, AM Colin-Jones, R Cutland, CL Darton, TC Dheda, K Duncan, CJA Emary, KRW Ewer, KJ Fairlie, L Faust, SN Feng, S Ferreira, DM Finn, A Goodman, AL Green, CM Green, CA Heath, PT Hill, C Hill, H Hirsch, I Hodgson, SHC Izu, A Jackson, S Jenkin, D Joe, CCD Kerridge, S Koen, A Kwatra, G Lazarus, R Lawrie, AM Lelliott, A Libri, V Lillie, PJ Mallory, R Mendes, AVA Milan, EP Minassian, AM Lambe, T Pollard, AJ |
| author2 | Oxford COVID Vaccine Trial Group |
| author_facet | Oxford COVID Vaccine Trial Group Voysey, M Clemens, SAC Madhi, SA Weckx, LY Folegatti, PM Aley, PK Angus, B Baillie, VL Barnabas, SL Bhorat, QE Bibi, S Briner, C Cicconi, P Collins, AM Colin-Jones, R Cutland, CL Darton, TC Dheda, K Duncan, CJA Emary, KRW Ewer, KJ Fairlie, L Faust, SN Feng, S Ferreira, DM Finn, A Goodman, AL Green, CM Green, CA Heath, PT Hill, C Hill, H Hirsch, I Hodgson, SHC Izu, A Jackson, S Jenkin, D Joe, CCD Kerridge, S Koen, A Kwatra, G Lazarus, R Lawrie, AM Lelliott, A Libri, V Lillie, PJ Mallory, R Mendes, AVA Milan, EP Minassian, AM Lambe, T Pollard, AJ |
| author_sort | Voysey, M |
| collection | OXFORD |
| description | <p><strong>Background:</strong><br />
A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials.</p><br />
<p><strong>Methods:</strong><br />
This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674.</p><br />
<p><strong>Findings:</strong><br />
Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation.</p><br />
<p><strong>Interpretation:</strong><br />
ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.</p> |
| first_indexed | 2024-03-06T19:14:12Z |
| format | Journal article |
| id | oxford-uuid:17ca122f-c9df-4335-99fc-77c6da37d2e4 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:14:12Z |
| publishDate | 2020 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:17ca122f-c9df-4335-99fc-77c6da37d2e42022-03-26T10:39:37ZSafety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:17ca122f-c9df-4335-99fc-77c6da37d2e4EnglishSymplectic ElementsElsevier2020Voysey, MClemens, SACMadhi, SAWeckx, LYFolegatti, PMAley, PKAngus, BBaillie, VLBarnabas, SLBhorat, QEBibi, SBriner, CCicconi, PCollins, AMColin-Jones, RCutland, CLDarton, TCDheda, KDuncan, CJAEmary, KRWEwer, KJFairlie, LFaust, SNFeng, SFerreira, DMFinn, AGoodman, ALGreen, CMGreen, CAHeath, PTHill, CHill, HHirsch, IHodgson, SHCIzu, AJackson, SJenkin, DJoe, CCDKerridge, SKoen, AKwatra, GLazarus, RLawrie, AMLelliott, ALibri, VLillie, PJMallory, RMendes, AVAMilan, EPMinassian, AMLambe, TPollard, AJOxford COVID Vaccine Trial Group<p><strong>Background:</strong><br /> A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials.</p><br /> <p><strong>Methods:</strong><br /> This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674.</p><br /> <p><strong>Findings:</strong><br /> Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation.</p><br /> <p><strong>Interpretation:</strong><br /> ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.</p> |
| spellingShingle | Voysey, M Clemens, SAC Madhi, SA Weckx, LY Folegatti, PM Aley, PK Angus, B Baillie, VL Barnabas, SL Bhorat, QE Bibi, S Briner, C Cicconi, P Collins, AM Colin-Jones, R Cutland, CL Darton, TC Dheda, K Duncan, CJA Emary, KRW Ewer, KJ Fairlie, L Faust, SN Feng, S Ferreira, DM Finn, A Goodman, AL Green, CM Green, CA Heath, PT Hill, C Hill, H Hirsch, I Hodgson, SHC Izu, A Jackson, S Jenkin, D Joe, CCD Kerridge, S Koen, A Kwatra, G Lazarus, R Lawrie, AM Lelliott, A Libri, V Lillie, PJ Mallory, R Mendes, AVA Milan, EP Minassian, AM Lambe, T Pollard, AJ Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK |
| title | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK |
| title_full | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK |
| title_fullStr | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK |
| title_full_unstemmed | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK |
| title_short | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK |
| title_sort | safety and efficacy of the chadox1 ncov 19 vaccine azd1222 against sars cov 2 an interim analysis of four randomised controlled trials in brazil south africa and the uk |
| work_keys_str_mv | AT voyseym safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT clemenssac safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT madhisa safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT weckxly safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT folegattipm safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT aleypk safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT angusb safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT baillievl safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT barnabassl safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT bhoratqe safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT bibis safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT brinerc safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT cicconip safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT collinsam safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT colinjonesr safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT cutlandcl safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT dartontc safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT dhedak safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT duncancja safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT emarykrw safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT ewerkj safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT fairliel safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT faustsn safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT fengs safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT ferreiradm safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT finna safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT goodmanal safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT greencm safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT greenca safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT heathpt safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT hillc safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT hillh safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT hirschi safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT hodgsonshc safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT izua safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT jacksons safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT jenkind safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT joeccd safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT kerridges safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT koena safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT kwatrag safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT lazarusr safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT lawrieam safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT lelliotta safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT libriv safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT lilliepj safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT malloryr safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT mendesava safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT milanep safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT minassianam safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT lambet safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk AT pollardaj safetyandefficacyofthechadox1ncov19vaccineazd1222againstsarscov2aninterimanalysisoffourrandomisedcontrolledtrialsinbrazilsouthafricaandtheuk |